Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q2 2021 · 10-Q
Revenue$10.22B$10.22B+39.5% vs Q2 2020 Net Income$1.19B$1.19B+121.4% vs Q2 2020 EPS Diluted$0.66$0.66+120.0% vs Q2 2020 Operating Income$1,392,000,000+107.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,715,000,000+152.2% Margins · derivedOperating margin13.6%+4.4 pt vs Q2 2020
Net margin11.6%+4.3 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 4, 2021 · 35 d after period end